Percentage of people who reported different adverse events on the male injectable combination contraceptive, the female combined oral contraceptive, the female intrauterine system, the female vaginal ring, the female injection, the female transdermal system, and combined oral contraception during the 1956 trial
| Adverse Event | Contraceptive | AE frequency (%) | Sample size (n) | Publication | |
| Men | Women | ||||
| Acne | Injectable combination male contraceptive | 45.9 | 320 | Behre et al 20168 | |
| COC | 5.1 | 1723 | Ortho Tri-Cyclen Lo11 | ||
| IUS | 6.8* | 5091 | Mirena15 | ||
| Vaginal ring | 2.4 | 2501 | NuvaRing17 | ||
| Transdermal System | 2.9 | 3322 | Ortho Evra18 | ||
| Injection | 1.2 | >3900 | Depo-Provera16 | ||
| Libido decrease | Injectable combination male contraceptive | 4.1 | 320 | Behre et al 20168 | |
| COC (1959) | 22 | 830 | Pincus et al 195919 | ||
| Vaginal ring | 2 | 2501 | NuvaRing17 | ||
| Injection | 5.5 | >3900 | Depo-Provera16 | ||
| Libido increase | Injectable combination male contraceptive | 38.1 | 320 | Behre et al 20168 | |
| COC (1959) | 20 | 830 | Pincus et al 195919 | ||
| Pelvic pain | Injectable combination male contraceptive | 1.9 | 320 | Behre et al 20168 | |
| COC | 5.6 | 4826 | Ortho Tri-Cyclen14 | ||
| COC | 9.2 | 1723 | Ortho Tri-Cyclen Lo11 | ||
| IUS | 22.6* | 5091 | Mirena15 | ||
| Vaginal ring | 7.2 | 2501 | NuvaRing17 | ||
| Transdermal system | 8.1 | 3322 | Ortho Evra18 | ||
| Injection | 11.2 | >3900 | Depo-Provera16 | ||
| Weight gain | Injectable combination male contraceptive | 3.8 | 320 | Behre et al 20168 | |
| COC (1959) | 55 | 830 | Pincus et al 195919 | ||
| COC | 2.4 | 1723 | Ortho Tri-Cyclen Lo11 | ||
| Vaginal ring | 4.9 | 2501 | NuvaRing17 | ||
| Transdermal system | 2.7 | 3322 | Ortho Evra18 | ||
| Injection | 37.7 | >3900 | Depo-Provera16 | ||
| Mood changes | Injectable combination male contraceptive | 31.7 | 320 | Behre et al 20168 | |
| COC | 2.2 | 1056 | Yaz13 | ||
| COC | 2.3 | 2837 | Yasmin12 | ||
| COC | 3.8 | 4826 | Ortho Tri-Cyclen14 | ||
| COC | 7.6 | 1723 | Ortho Tri-Cyclen Lo11 | ||
| IUS | 6.4* | 5091 | Mirena15 | ||
| Injection | 1.5 | >3900 | Depo-Provera16 | ||
| Vaginal ring | 6.4 | 2501 | NuvaRing17 | ||
| Transdermal system | 6.3 | 3322 | Ortho Evra18 | ||
| Headache | Injectable combination male contraceptive | 5.3 | 320 | Behre et al 20168 | |
| COC | 6.7 | 1056 | Yaz13 | ||
| COC | 10.7 | 2837 | Yasmin12 | ||
| COC | 33.6 | 4826 | Ortho Tri-Cyclen14 | ||
| COC | 30.5 | 1723 | Ortho Tri-Cyclen Lo11 | ||
| IUS | 16.3* | 5091 | Mirena15 | ||
| Vaginal ring | 11.2 | 2501 | NuvaRing17 | ||
| Transdermal system | 21.0 | 3322 | Ortho Evra18 | ||
*Crude incidence per person-years.
AE, adverse event; COC, combined oral contraceptive; IUS, intrauterine system.